Following a survey on the clinical practice of geriatricians in the management of older people with diabetes and a study of hypoglycaemia in diabetic patients, a round-table discussion with geriatricians and endocrinologists was held in January 2015. Consensus was reached for six domains specifically related to older diabetic people: (1) the considerations when setting an individualised diabetic management; (2) inclusion of geriatric syndrome screening in assessment; (3) glycaemic and blood pressure targets; (4) pharmacotherapy; (5) restrictive diabetic diet; and (6) management goals for nursing home residents.
Introduction
The prevalence of diabetes increases with age such that among the older population (age ≥65 years), it was 6 times that of the younger population (age 18-64 years), reaching 21.4% in Hong Kong in 2004 to 2005. 1 Although the prevalence among older people is quite constant over time, with an ageing population the number of older people with diabetes is expected to continuously increase in the future.
In addition to the increasing population of older diabetic people, heterogeneity among older people with varying levels of cognitive and functional ability, life expectancy, and social support present a challenge in clinical practice because there is no single treatment goal or management plan that can address all of the issues in this patient group. Recently, individualised and tailored care approaches to cater for the individual characteristics of older people have been promoted. [2] [3] [4] [5] [6] [7] Increasing attention to avoid treatment-related hypoglycaemia has also been emphasised. [2] [3] [4] [5] [6] [7] However, there is a gap in knowledge of the optimal management due to the paucity of clinical trials among older diabetic people, in particular those with frailty. This has led to a lack of consensus and variation of management in clinical practice.
A special interest group on diabetes mellitus, under the auspices of The Hong Kong Geriatrics Society (HKGS), has been established to raise the awareness of diabetes among older people; to address the special issues of older people associated with their varied physical, cognitive, and social needs; and to enhance their care. A survey on the opinions of local geriatricians about diabetes management in older people and data analysis of hypoglycaemia among diabetic patients in the local public sector were performed. A round-table discussion with geriatricians from the HKGS and endocrinologists from the Hong Kong Society of Endocrinology, Metabolism and Reproduction was then held on 24 January 2015. Discussion was based on evidence-based review of the current literature, scientific presentations by experts in the field, opinions from both geriatricians and endocrinologists, and the analysis of local data on hypoglycaemia of the diabetic patients. After the meeting, statements were drafted and circulated among the council members of HKGS and the Hong 
Individualised diabetes management
Most (60%) of the respondents ranked risk of hypoglycaemia as the most important domain in setting an individualised diabetes management plan. Physical and mental functions, and co-morbidities and associated vascular diseases were also considered to be important.
Geriatric syndromes
Almost all of the respondents agreed that physical frailty (98%) and cognitive impairment (96%) should be assessed when managing older people with diabetes. More than 80% of respondents agreed that polypharmacy and nutritional problems should also be assessed.
Target glycaemic and blood pressure control
Respondents agreed that an individual's comorbidities, cognitive and functional status, and life expectancy must be considered when determining a glycaemic goal, such that more stringent control (target glycated haemoglobin [HbA1c] 6.5%-7%) should be considered for robust elderly people (59% of respondents), less stringent control (target HbA1c 7%-9%) for those who are physically frail or cognitively impaired (52%-57% of respondents), and relaxed control (target HbA1c ≥9%) for those receiving end-of-life care (50% of respondents). Blood pressure targets set for older diabetic people were quite varied among the respondents; these ranged from ≤130/80 mm Hg to ≤150/90 mm Hg for robust elderly people, and ≤160/100 mm Hg and avoidance of diastolic blood pressure of <60 mm Hg for those at the end of life.
Pharmacotherapy
The risk of hypoglycaemia was the most important concern for almost all the respondents (98%) when prescribing glucose-lowering therapy. Dosing frequency was also a major concern (76% of respondents). A vast majority (93% of respondents) would prescribe metformin as the first-line glucoselowering therapy for robust elderly people, while a dipeptidyl peptidase-IV (DPP-IV) inhibitor (45%) or sulphonylurea (45%) was considered suitable for older people with organ failure or estimated glomerular filtration rate of <30 mL/min, and metformin (52%) and a DPP-IV inhibitor (34%) was considered suitable for those at high risk of hypoglycaemia.
Non-pharmacotherapy
A majority (>80%) of respondents considered that a restrictive diabetic diet should only be allocated for robust elderly people, but not for octogenarians, physically frail or cognitively impaired patients, and nursing home residents.
Goals for nursing home residents
Preventing hypoglycaemia was the goal of almost all the respondents (98%). This was followed by preventing hospitalisation and avoiding acute metabolic complications (approximately 80% of respondents).
A study of hypoglycaemia in diabetic patients in Hong Kong
A study of hypoglycaemia in the older diabetic population was performed. Table 2 ]. Tight glycaemic control with HbA1c of ≤7% was associated with a significantly higher 12-month mortality in older diabetic patients than those with less stringent control (27.8% vs 11.8%; P=0.04).
In addition, older patients with very tight glycaemic control (HbA1c ≤6%) had a longer duration of stay in hospital than those with less stringent control (6.8 days vs 3.8 days; P=0.001). On the other hand, loose glycaemic control with HbA1c of ≤8% and patients aged younger than 65 years were not associated with increased short-term (28-day readmission) and long-term (12-month mortality) adverse outcomes. Multivariate analysis showed that male sex, higher Charlson Comorbidity Index score, dementia, and lower HbA1c level were independent predictors for 12-month mortality among the older diabetic patients (Table 3 ).
Factors to be considered in the management of older people with type 2 diabetes mellitus

Hypoglycaemic risk
Advanced age is an independent risk factor for hypoglycaemia. 8 Older people are intrinsically prone to hypoglycaemia. With increasing age, hypoglycaemic warning symptoms become less intense and hypoglycaemic unawareness becomes more common even with intact physiological glucose counter-regulatory response (ie decreased insulin Abbreviations: DAMA = discharge against medical advice; LOS = length of stay; NA = not applicable; OAH = old-age home; SD = standard deviation * 78.2% Of all adult patients † Comparison of clinical characteristics between age <65 years and age ≥65 years was performed by Student's t test ‡ Up to 15 January 2015 secretion, and increased glucagon and epinephrine secretion). [9] [10] [11] [12] Furthermore, the physiologically higher blood glucose level for the initiation of neurogenic warning symptoms (eg palpitation, tremor, and sweating-the result of automonic activation) than that for onset of neuroglycopenic symptoms (eg confusion, seizure, and loss of consciousness-the result of brain glucose deprivation), which allows time to take measures to avoid neuroglycopenia and severe hypoglycaemia, tends to be lost in the older people. 12 The impaired perception of the warning symptoms of hypoglycaemia and the narrower or even absence of a glycaemic threshold gap between the development of neurogenic and neuroglycopenic symptoms put elderly people at a high risk for severe hypoglycaemia.
Furthermore, with a longer duration of type 2 diabetes and subsequent progression to endogenous insulin deficiency, counter-regulatory responses to hypoglycaemia are compromised. Additionally, the neurogenic warning symptoms become attenuated and lead to hypoglycaemic unawareness. Compromised glucose counter-regulation and hypoglycaemia unawareness increase the risk of severe iatrogenic hypoglycaemia by 25-fold and 6-fold, respectively. 13, 14 Multiple co-morbidities, polypharmacy, and cognitive dysfunction associated with advancing age are also risk factors for hypoglycaemia (see below).
Geriatric syndromes
Diabetes predisposes older people to the development of geriatric syndromes as it is associated with risk for dementia, depression, polypharmacy, fall and fracture, urinary incontinence, visual impairment, and chronic pain. The presence of geriatric syndromes is linked with functional decline and increasing frailty that would limit a patient's functional independence and complicate medical management. Early recognition and including geriatric syndromes in the management plan are recommended. 
Cognitive dysfunction
Patients with diabetes are at increased risk for dementia. They have been shown to have a 1.2-to 1.5-fold higher rate of decline in cognitive function than those without diabetes, 15 and were at a higher risk for developing Alzheimer's disease and vascular dementia by approximately 1.5-fold and 2.5-fold, respectively. 16 Additionally, adverse effect of treatment-related hypoglycaemia, especially if it is severe, has been shown to be associated with subsequent dementia in older diabetic patients. [17] [18] [19] There was also a graded increase in dementia risk with the number of severe hypoglycaemic episodes experienced, such that the risk was almost double for three or more episodes when compared with only one episode. 17 Furthermore, there is a bidirectional association of hypoglycaemia with dementia in which hypoglycaemia damages the brain and that, in turn, decreases one's ability to manage diabetes or recognise hypoglycaemic symptoms leading to the subsequent risk of hypoglycaemia, that further impairs cognitive function in a vicious cycle.
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Depression
A systematic review and meta-analysis found people with type 2 diabetes had a 24% increased risk of developing depression. 21 On the other hand, depression was associated with a 60% increased risk of type 2 diabetes in another systematic review. 22 Despite the fact that depression in diabetic patients is common, it is often undiagnosed and untreated. 23 Like cognitive dysfunction, depression may impede functionality and diabetic self-management causing erratic timing of medication intake, irregular eating, inability to self-monitor blood glucose, and failure to recognise hypoglycaemic symptoms to enable prompt management. These may worsen glycaemic control and increase the risk of diabetic and treatment-related complications. Early detection of depression, especially in those with unexplained decline in clinical status, is warranted. 24 
Polypharmacy
Medications prescribed for co-morbidities predispose patients to the impact of polypharmacy. Because of the age-related changes in pharmacokinetics and pharmacodynamics, the adverse effects of drugs and drug-drug interactions are further exacerbated in older patients. Older diabetic patients using four or more concomitant medications have been found to be at increased risk for developing serious hypoglycaemia. 8, 25 Polypharmacy can also precipitate geriatric syndromes such as fall, cognitive impairment, urinary incontinence, and malnutrition.
26,27
Fall and fracture
Diabetic complications (such as autonomic dysfunction with orthostatic hypotension, peripheral neuropathy with gait disorder, and diabetic retinopathy with poor vision) 28 and treatment complications (such as metforminassociated vitamin B 12 deficiency with resultant neuropathy) 29 increase the susceptibility of diabetic patients to fall. Besides, diabetes has been shown to be an independent risk factor for fracture. 30 Patients who have longer diabetes duration, suboptimal glucose control, diabetic retinopathy, insulin use or thiazolidinedione use in women, and increased risk for fall are particularly at high risk for fracture.
30-32
Chronic pain and urinary incontinence
Neuropathic pain affects up to one third of patients with diabetes and is more prevalent in women. 33 Its occurrence may not relate to the severity of neuropathy and may even occur in patients without clinical neuropathy. Besides, pain from other sources such as bone, joint, and back is common in older people. Urinary incontinence is also common in diabetic patients, especially women. Up to one third of female patients with diabetes had reported incontinence at least weekly in a survey in which urge incontinence was associated with advancing age. 34 Managing treatable causes such as urinary tract infection, faecal impaction, use of offensive medications, and poor glycaemic control with polyuria may alleviate incontinence. 24 Both pain and urinary incontinence are often neglected in clinical practice and may lead to adverse outcomes such as anxiety, depression, decreased socialisation, fall and fracture if left untreated.
35-37
Co-morbidities and other cardiovascular risk factors
As many as 40% of older people with diabetes have four or more chronic conditions. 38 Multiple comorbidities may have profound effects on patients' ability to self-care. Additionally, the level of comorbidities affects treatment outcomes. Diabetic patients with low-to-moderate co-morbidity have been found to have a lower incidence of cardiovascular events than those with high co-morbidity, even with comparable HbA1c levels. 39 Furthermore, comorbidity, especially renal impairment, hepatic disease and cognitive dysfunction increase the risk of severe hypoglycaemia, 25 which is associated with twice the risk of cardiovascular disease (myocardial infarction, congestive heart failure, stroke, and cardiovascular death) in diabetic patients. 40 Diabetic patients with concomitant coronary artery disease who experience hypoglycaemia are particularly prone to ischaemic heart attack. 41 These have clinical implications-in patients with multiple comorbidities, intensive glucose treatment may not be beneficial, but might make patients prone to treatment-related hypoglycaemia which, in turn, may exacerbate the cardiovascular event, especially in those at risk for cardiovascular disease.
Management of other cardiovascular factors to lower the cardiovascular risk is also important. Systolic blood pressure (SBP) of ≥140 mm Hg increases the risk of cardiovascular events, whereas lowering blood pressure from a high level reduces both cardiovascular and microvascular complications in older diabetic patients. [42] [43] [44] There is no further benefit to lowering SBP to <130 mm Hg however, as compared to SBP of 130-140 mm Hg, but may increase mortality. 45, 46 Furthermore, a low diastolic blood pressure of <70 mm Hg that may result from SBP reduction is associated with higher cardiovascular disease risk. 42 Thus, the recommended target blood pressure for older diabetic patients is <140/90 mm Hg, if tolerated. 2 Lipid lowering by statins has been shown to reduce the incidents of major vascular events by approximately 20% per mmol/L low-density lipoprotein cholesterol reduction in diabetic patients and in patients age ≥65 years. 47 This benefit emerges quite rapidly, within 1 to 2 years of treatment, suggesting that most older people could benefit from statins except for those with very limited life expectancy. There is limited evidence with drugs other than statins for reduction of cardiovascular risk.
Is stringent glycaemic control beneficial?
The UKPDS (UK Prospective Diabetes Study) that recruited patients with newly diagnosed type 2 diabetes (mean age, 53 years) showed a 25% risk reduction in microvascular complications in the intensive-therapy group (HbA1c achieved, 7%) after a median follow-up of 11 years. 48 Macrovascular benefit, in terms of a 15% risk reduction for myocardial infarction, emerged only during 10 years of extended post-trial follow-up. 49 In three more recent large-scale trials-ACCORD (Action to Control Cardiovascular Risk in Diabetes), ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation), and VADT (Veterans Affairs Diabetes Trial)-which recruited older people (mean age, 60-66 years) with type 2 diabetes duration of 8 to 11.5 years and of whom 32% to 40% had a history of cardiovascular events, the intensive-therapy group (HbA1c achieved, 6.4%-6.9%) showed no benefit in the reduction of overall major cardiovascular events and death over 5 years of follow-up but only a lower rate of non-fatal myocardial infarction in the ACCORD trial. [50] [51] [52] [53] Instead, there was higher mortality in the intensive-therapy group of the ACCORD trial that led to premature discontinuation of intensive therapy after 3.5 years of follow-up. For the microvascular outcomes, the intensivetherapy group had lowered macroalbuminuria by 30%, decreased progression of retinopathy by 33%, and a modest risk reduction in the development of peripheral neuropathy. 51, 54, 55 All of these trials revealed that intensive therapy was associated with a higher rate of hypoglycaemic episodes, with up to 2-to 3-fold increase in severe hypoglycaemia. The findings imply that good glycaemic control is most beneficial if it commences earlier, before the establishment of long-term complications. Furthermore, it takes time for intensive glycaemic control to reap microvascular benefit (over 5 years) and even longer for macrovascular benefit (over 10-20 years). 48, 49, 51, 52, 54, 55 For patients with limited life expectancy and multiple co-morbidities, the adverse effects are likely to outweigh the benefits.
Individualised approach
The primary aim of diabetes management is to optimise glycaemic control to avoid acute hyperglycaemia complications and prevent longterm diabetic complications, both microvascular and macrovascular, and to minimise the adverse effect of treatment-related hypoglycaemia. Given the heterogeneous health status of older people, diabetes intervention strategies designed for long-term benefits may not be appropriate for all older people. A patient-centred approach for diabetes management that takes account of the potential benefits and risks of treatment, health and functional state, and social background for an individual patient has been increasingly emphasised. Accordingly, various frameworks or guidelines have been developed to assist in determining glycaemic treatment goals in older diabetic patients. [2] [3] [4] [5] [6] In general, for older people who are relatively young, healthy and active, the same glycaemic target as for young people may be worthwhile to prevent long-term complications. For frail older people with multiple co-morbidities and limited life expectancy, the aim of glycaemic control is to prevent acute hyperglycaemic complications (polyuria, dehydration, hyperglycaemic hyperosmolar syndrome, infection, and poor wound healing) while avoiding treatment adverse effects, rather than to gain long-term benefit. The suggested target HbA1c varies from 7.0% to 7.5% for healthy older people to 8% to 9% for those who are in very poor health. [2] [3] [4] [5] [6] The choice of anti-glycaemic agents should focus on safety, with low risk for hypoglycaemia, and metformin is generally considered to be the first-line therapy for older people.
2-6 Avoidance of drugs with potential adverse effects that may exacerbate underlying conditions such as heart failure, osteoporosis with risk of fracture, and renal dysfunction is also advised.
Restrictive diabetic diet
Because of altered taste and smell, anorexia of ageing, difficulty in swallowing, and decreased functional state, food intake tends to decline with advancing age. A restrictive diet for glycaemic control that is designed for young and middle-aged diabetic patients may not be suitable for all older diabetic patients. 56 Instead, a restrictive diet may limit the variety and flavour of food offered, which may exacerbate poor food intake leading to unintentional weight loss and undernutrition. Those who are frail, institutionalised, or underweight are particularly at risk, with increased morbidity and mortality. 57 Thus, a less restrictive diet or even a liberal diet with modification of medications to control blood glucose may be advisable for susceptible patients. 58 Nutritional assessment taking account of a patient's circumstances to guide individual nutritional intervention is advocated. 
Consensus
Conclusion
With the increasing population of older people with diabetes and the complexity and heterogeneity of older people, it is time to change our clinical practice in managing diabetes in older peoplemanagement should not be solely based on the clinical guidance for younger people with diabetes. We need to consider the course of the disease in the context of individual characteristics (co-morbidities, frailty, cognitive impairment, life expectancy, risk of treatment-induced hypoglycaemia, patients' attitudes, social support, etc) to tailor a treatment goal and management plan. This approach has recently been advocated by several international organisations such as the American Diabetes Association and the American Geriatrics Society. Our consensus statement takes the initiative in promoting better diabetes care for older people in our locality. The guidance takes into consideration of local experience to address issues specifically related to older diabetic people, such as the inclusion of a comprehensive geriatric assessment to screen for geriatric syndromes and psychosocial needs, which is often missed in a busy clinic, and the glycaemic targets for broadly classified groups of patients, which could guide clinicians in daily practice. Nonetheless, the consensus statement is far from complete in addressing all the issues-the details on how to implement the geriatric assessment for optimal therapy, the appropriate treatment goals for all the multifaceted scenarios of older people, the optimal level of blood pressure control, and the allocation of social support for care in the community and much more, remain to be determined.
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